Organization
United BioPharma
8 clinical trials
Clinical trial
A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected AdultsStatus: Withdrawn, Estimated PCD: 2025-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial With UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 InfectionStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase II, Double-blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous UrticariaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 InfectionStatus: , Estimated PCD: 2024-03-01
Clinical trial
A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART InterruptionStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive PatientsStatus: Completed, Estimated PCD: 2022-05-25
Clinical trial
A Two-Stage, Randomized, Double-Blind, Dose-Ranging, Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 on HSV Shedding in Adults With Recurrent Genital HSV-2 Infection.Status: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous UrticariaStatus: Not yet recruiting, Estimated PCD: 2024-11-30